Efficacy and safety of Lutetim-177-PSMA-617 therapy in paitents with metastatic prostate cancer after radical prostatectomyand bilateral orchitectomy
Phase 2
- Conditions
- Prostate cancer.Malignant neoplasm of prostate
- Registration Number
- IRCT20230414057906N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
Men with metastatic prostate cancer after radical prostatectomy and bilateral orchitectomy
68Ga-PSMA-PET/CT positive scan
Having willingness to participate in this study
Exclusion Criteria
Creatinine >=2 mg/dl
Obstructive DTPA SCAN
GFR=30
WBC=2000
Hb=8g/dl
Previous history of chemotherapy/radiotherapy for prostate cancer
PLAT=75000
ALT/AST >5 times of upper normal limit for those with liver metastasis or <2 times for those without liver metastasis.
Patients with life expectancy <12 weeks
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method